Elamin H Elbasha
Overview
Explore the profile of Elamin H Elbasha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
950
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nwankwo C, Corman S, Elbasha E
J Infect Public Health
. 2019 Feb;
12(4):502-508.
PMID: 30711348
Background: Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in patients with chronic kidney disease (CKD). The objective of this study was to predict the...
12.
Yamabe K, Singhal P, Abe M, Dasbach E, Elbasha E
Value Health Reg Issues
. 2018 Apr;
2(1):92-97.
PMID: 29702859
Objective: We assessed the epidemiological and economic impact of a quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for females in preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN...
13.
Hayajneh W, Daniels V, James C, Kanibir M, Pilsbury M, Marks M, et al.
BMC Infect Dis
. 2018 Mar;
18(1):119.
PMID: 29514609
Background: As the socioeconomic conditions in Jordan have improved over recent decades the disease and economic burden of Hepatitis A has increased. The purpose of this study is to assess...
14.
Corman S, Elbasha E, Michalopoulos S, Nwankwo C
Value Health
. 2017 Oct;
20(8):1110-1120.
PMID: 28964443
Objective: To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3D ± RBV), and sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic...
15.
Dasbach E, Elbasha E
Pharmacoeconomics
. 2017 May;
35(7):673-683.
PMID: 28456972
Decision-analytic models for cost-effectiveness analysis are developed in a variety of software packages where the accuracy of the computer code is seldom verified. Although modeling guidelines recommend using state-of-the-art quality...
16.
Chhatwal J, Jayasuriya S, Elbasha E
Med Decis Making
. 2016 Jul;
36(8):952-64.
PMID: 27369084
The choice of a cycle length in state-transition models should be determined by the frequency of clinical events and interventions. Sometimes there is need to decrease the cycle length of...
17.
Elbasha E, Chhatwal J
Pharmacoeconomics
. 2015 Dec;
34(1):13-22.
PMID: 26643402
Commonly used decision-analytic models for cost-effectiveness analysis simulate time in discrete steps. Use of discrete-time steps can introduce errors when calculating cumulative outcomes such as costs and quality-adjusted life-years. There...
18.
Durham D, Skrip L, Bruce R, Vilarinho S, Elbasha E, Galvani A, et al.
Clin Infect Dis
. 2015 Dec;
62(3):298-304.
PMID: 26628566
Background: The effectiveness of interferon-free direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screening and treatment rates, particularly among people who inject drugs (PWIDs)....
19.
Elbasha E, Chhatwal J
Med Decis Making
. 2015 Jun;
36(1):115-31.
PMID: 26092831
Background: Modeling guidelines recommend applying a half-cycle correction (HCC) to outcomes from discrete-time state-transition models (DTSTMs). However, there is still no consensus on why and how to perform the correction....
20.
Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia M, Acosta C, et al.
Value Health
. 2015 Jun;
18(4):358-67.
PMID: 26091589
Objective: To assess the population-level impact and cost-effectiveness of hepatitis A vaccination programs in the United States. Methods: We developed an age-structured population model of hepatitis A transmission dynamics to...